Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial - supplementary table

Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis.
Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h)
or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients
with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group.
No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also
comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical
treatment of nosocomial sepsis without serious concern regarding its safety.

研究目的：旨在评估大剂量美罗培南作为医院获得性败血症经验性治疗的安全性。
研究方法：确诊为重症败血症的患者接受了高剂量（每8小时2克）或大剂量（每8小时4克）美罗培南静脉输注，持续3小时。结果：共有23名医院获得性败血症患者符合条件并被纳入大剂量（n = 11）或高剂量（n = 12）组。在14天的随访期间，未观察到与治疗相关的副作用。两组之间的临床反应也相似。结论：在无需过度担忧其安全性的情况下，大剂量美罗培南可能适用于医院获得性败血症的经验性治疗。